Suneet Varma was recently Global and U.S. President, Oncology. During his tenure, Pfizer rose to become the third largest oncology company in the USA in 2024 with an industry-leading portfolio of 25+ approved medicines across more than 40 indications.
Before leading Oncology, Suneet served as Global President of Rare Diseases, one of Pfizer’s fastest growing, high science units, which included a targeted gene therapy program.
Prior to that role, Suneet was the charter Global President of the Hospital Unit focused on both primary and alternative patient sites of care and therapeutic areas such as Anti-Infectives, Blood Management, Pain & Anesthesia amongst a dozen others. As part of this complex portfolio of ~300 treatments, approximately 50 medicines were also on the WHO essential medicines list. Further, he also over saw the company’s CDMO, Pfizer CentreOne and DoD unit, Meridian Medical Technologies, in this role.
